AU2019333119B2 - Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents - Google Patents

Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents Download PDF

Info

Publication number
AU2019333119B2
AU2019333119B2 AU2019333119A AU2019333119A AU2019333119B2 AU 2019333119 B2 AU2019333119 B2 AU 2019333119B2 AU 2019333119 A AU2019333119 A AU 2019333119A AU 2019333119 A AU2019333119 A AU 2019333119A AU 2019333119 B2 AU2019333119 B2 AU 2019333119B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019333119A
Other languages
English (en)
Other versions
AU2019333119A1 (en
Inventor
David Michael LONARD
Lisa Kay McCLENDON
Bert W. O'malley
Yongcheng Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2019333119A1 publication Critical patent/AU2019333119A1/en
Application granted granted Critical
Publication of AU2019333119B2 publication Critical patent/AU2019333119B2/en
Priority to AU2025226726A priority Critical patent/AU2025226726A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AU2019333119A 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents Active AU2019333119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025226726A AU2025226726A1 (en) 2018-08-29 2025-09-03 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724281P 2018-08-29 2018-08-29
US62/724,281 2018-08-29
US201962825358P 2019-03-28 2019-03-28
US62/825,358 2019-03-28
PCT/US2019/048703 WO2020047186A1 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025226726A Division AU2025226726A1 (en) 2018-08-29 2025-09-03 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Publications (2)

Publication Number Publication Date
AU2019333119A1 AU2019333119A1 (en) 2021-03-18
AU2019333119B2 true AU2019333119B2 (en) 2025-06-05

Family

ID=67982135

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019333119A Active AU2019333119B2 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
AU2025226726A Pending AU2025226726A1 (en) 2018-08-29 2025-09-03 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025226726A Pending AU2025226726A1 (en) 2018-08-29 2025-09-03 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Country Status (7)

Country Link
US (4) US10875841B2 (enExample)
EP (1) EP3843843A1 (enExample)
JP (3) JP7495138B2 (enExample)
CN (2) CN120136844A (enExample)
AU (2) AU2019333119B2 (enExample)
CA (1) CA3110839A1 (enExample)
WO (1) WO2020047186A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110839A1 (en) * 2018-08-29 2020-03-05 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
AU2021372270A1 (en) 2020-10-28 2023-06-22 Baylor College Of Medicine Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer
WO2025240566A1 (en) * 2024-05-17 2025-11-20 Baylor College Of Medicine Small molecule steroid receptor coactivator stimulators for use in repairing tissue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153508A (zh) * 2010-10-08 2011-08-17 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN106083704A (zh) * 2016-06-06 2016-11-09 福建医科大学 3,5‑(E)‑ 二芳亚甲基‑N‑环丙基哌啶‑4‑酮类化合物作为Hsp90抑制剂的应用
WO2019097080A1 (en) * 2017-11-20 2019-05-23 Kiakos Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
AU779230C (en) 1999-12-03 2006-05-25 Emory University Curcumin analogues for treating cancer
EP1242352A2 (en) 1999-12-23 2002-09-25 University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO2007007207A2 (en) 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
CN102381951B (zh) 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
US20100093611A1 (en) 2007-05-16 2010-04-15 Horrigan Stephen K Compounds and methods for treating or preventing autoimmune diseases
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
WO2009073050A2 (en) 2007-07-27 2009-06-11 Research Foundation Of City University Of New York Use of curcumin to block brain tumor formation in vivo
US8772265B2 (en) 2008-05-29 2014-07-08 Universite Libre De Bruxelles Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same
WO2011029359A1 (zh) 2009-09-12 2011-03-17 温州医学院 含11β-羟基甾体脱氢酶1双重调节剂的药物及其应用
JP2011074024A (ja) 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012021692A1 (en) 2010-08-11 2012-02-16 Rutgers, The State University Of New Jersey Curcumin analogs and methods of use thereof
CN103012088B (zh) 2012-11-28 2017-01-11 江苏药兴医药股份有限公司 α-(3,5-二甲氧基苯亚甲基)-α'-烃基亚甲基环酮及其制备方法
ITMI20130075A1 (it) 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
CN103181922A (zh) 2013-04-02 2013-07-03 温州医学院 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
CA3110839A1 (en) * 2018-08-29 2020-03-05 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153508A (zh) * 2010-10-08 2011-08-17 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN106083704A (zh) * 2016-06-06 2016-11-09 福建医科大学 3,5‑(E)‑ 二芳亚甲基‑N‑环丙基哌啶‑4‑酮类化合物作为Hsp90抑制剂的应用
WO2019097080A1 (en) * 2017-11-20 2019-05-23 Kiakos Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Huang, L. et al.; Eur. J. Med. Chem., 143, 1165-1173 (2018); DOI: 10.1016/j.ejmech.2017.09.028. *

Also Published As

Publication number Publication date
JP7495138B2 (ja) 2024-06-04
JP2021534221A (ja) 2021-12-09
US20200071300A1 (en) 2020-03-05
JP2024102352A (ja) 2024-07-30
CN112955217A (zh) 2021-06-11
US20230357200A1 (en) 2023-11-09
WO2020047186A1 (en) 2020-03-05
US20250282755A1 (en) 2025-09-11
US20210115017A1 (en) 2021-04-22
CN112955217B (zh) 2025-04-08
JP7777263B2 (ja) 2025-11-28
AU2025226726A1 (en) 2025-09-25
CA3110839A1 (en) 2020-03-05
CN120136844A (zh) 2025-06-13
AU2019333119A1 (en) 2021-03-18
JP2025183370A (ja) 2025-12-16
US12338229B2 (en) 2025-06-24
US11708350B2 (en) 2023-07-25
US10875841B2 (en) 2020-12-29
EP3843843A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US12338229B2 (en) Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
Davidson et al. Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart
Yan et al. Lingzhilactones from Ganoderma lingzhi ameliorate adriamycin-induced nephropathy in mice
Cui et al. Baicalein represses TGF-β1-induced fibroblast differentiation through the inhibition of miR-21
Paul et al. Cytotoxicity mechanism of non-viral carriers polyethylenimine and poly-l-lysine using real time high-content cellular assay
EP3104847B1 (en) Novel use of sigma-1 receptor agonist compounds
KR101780456B1 (ko) 크로몬 유도체의 상피간엽이행 억제 활성을 이용한 섬유증 예방 및 치료용 약제학적 조성물로서의 새로운 용도
Zhu et al. Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p
Fang et al. Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy
Fang et al. Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway
Huang et al. Secoisolariciresinol diglucoside prevents the oxidative stress-induced apoptosis of myocardial cells through activation of the JAK2/STAT3 signaling pathway
US20180265444A1 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
Kumar et al. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis
Cristofaro et al. Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells
Wang et al. A novel and low-toxic peptide DR3penA alleviates pulmonary fibrosis by regulating the MAPK/miR-23b-5p/AQP5 signaling axis
Zhang et al. Tanshinone IIA triggers p53 responses and apoptosis by RNA polymerase II upon DNA minor groove binding
CN106132417A (zh) 低分子化合物的癌症以及纤维化抑制效果
US10450295B2 (en) Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
US20250003952A1 (en) Senolytic drug screening method and senolytic drug
Gao et al. Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study
CN121129836A (zh) P7c3在制备抑制肝纤维化药物制剂中的应用
US20130289073A1 (en) Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
WO2008106524A1 (en) Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US20030181506A1 (en) Selective preventives/remedies for progressive lesions after organ damage
Yao et al. Design, synthesis and biological assessment of erlotinib-1, 2, 3-triazole derivatives for anticancer applications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ O'MALLEY, BERT W.; LONARD, DAVID MICHAEL; SONG, YONGCHENG AND MCCLENDON, LISA KAY

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ O'MALLEY, BERT W.; LONARD, DAVID MICHAEL; SONG, YONGCHENG AND MCCLENDON, LISA KAY